

Saturday (27.10.2018)	Sunday (28.10.2018)	Monday (29.10.2018)	
	07:30 – 09:00 Interactive Case Discussion (Faculty: M. Hertzberg, A. Lister / Presenters: D. A. Eichenauer, J. Romejko-Jarosinska, O. Baiocchi, S. Borchmann) 1. Stage IV NPLHL (D. Eichenauer) 2. Elderly cHL (J. Romejko-Jarosinska) 3. HIV-positive HL (O. Baiocchi) 4. Progress on anti-PD1 moAb (S. Borchmann)	07:30 – 09:00 Advanced Stages (V. Diehl, P. Johnson) • ECHOLON1 Update (J. Radford) • HD18 Update (P. Borchmann) • LYSA AHL2011 Phase III Study (O. Casasnovas)	07:30
08:45 – 10:15 Workshops • Radiotherapy in Salvage (S. Marnitz-Schulze, J. Yahalom) • Molecular Pathogenesis (M. L. Hansmann, C. Steidl) • Developing Health Care Environments (A. Hagenbeek, O. Henke) • Positron Emission Tomography (M. Dietlein, M. Meignan)	Coffee Break	Oral Abstract Presentations	09:00
Coffee Break	09:15 – 10:15 Oncology meets Autoimmunity by Chugai (A. Engert) • Autotransplant in systemic sclerosis (J. Henes) • Autoimmunity in chronic GVHD (D. Wolff)	Coffee Break	09:15
10:30 – 12:00 Workshops • Survivorship (F. van Leeuwen, A. Plate) • Immunotherapy: Chances & Pitfalls (P. Armand, T. Illidge) • Challenges in Older Lymphoma Patients (P. Brice, J. Friedberg) • Minimum Residual Disease (A. Hagenbeek, P. L. Zinzani)	10:30 – 12:00 Biology & Microenvironment (A. van den Berg, C. Steidl) • Microenvironment (R. Küppers) • Genotyping of cHL via Liquid Biopsy (D. Rossi)	09:15 – 10:15 CAR T Cell Therapies: Hype Or Hope? by Celgene (H. Einsele) • Preclinical Rationale for CAR T Cell Therapy (S. Thomas) • CD19 directed CAR T Cell Therapy in B-NHL (P. Borchmann) • BCMA directed CAR T Cell Therapy in MM (H. Einsele)	10:15
Coffee Break	Coffee Break	Coffee Break	10:30
12:15 – 13:45 Biosimilar rituximab – a new treatment option by Sandoz Germany (A. Engert) • Biosimilar Development in Oncology (T. Dingermann) • Clinical evidence for biosimilar rituximab (N. N.) • Treatment of CD20 positive, lymphocyte-predominant Hodgkin Lymphoma (D. Eichenauer)	12:15 – 13:45 HL: Tailoring sequencing and treatment targets. by Takeda (P. Borchmann) • Welcome and introduction (P. Borchmann) • Considering consolidation after autologous stem cell transplantation (D. Molin) • Relapse after autologous transplant: options and optimising outcomes (A. Sureda) • Considering patient factors: challenging cases and clinical management (All, Facilitated by P. Borchmann)	10:30 – 12:00 Pediatric HL (C. Mauz-Körholz, K. M. Kelly) • PD1/L1 Expression in Pediatric HL (S. Gattenlöhner) • Genotyping in Familial HL (J. Yang) • Functional and Financial Outcomes after Treatment for Pediatric Hodgkin Lymphoma (S. Parsons)	10:30
Coffee Break	Coffee Break	Coffee Break	12:00
14:00 – 15:30 Immunotherapy – Biomechanisms (A. Rosenwald, M. Shipp) • T-cells and PD1 Inhibition in cHL (M. Shipp) • Immune-Evasion (M. K. Gandhi)	14:00 – 15:30 Early Stages (R. Hoppe, J. Raemaekers) • Early-Stage Favorable HL: HD16 (A. Engert) • BREACH: Randomized Phase II Trial (M. André)	12:15 – 13:45 Checkpointblockade in Lymphomas by MSD (A. Engert) • Basics in immunotherapy for lymphomas (D. Wolf) • PD-1 blockade current and future aspects of cHL therapy (P. Borchmann) • PD-1 blockade in NHLs (P. L. Zinzani)	12:15
Coffee Break	Coffee Break	Coffee Break	13:45
16:00 – 17:30 Immunotherapy – Biomechanisms (A. Rosenwald, M. Shipp) • T-cells and PD1 Inhibition in cHL (M. Shipp) • Immune-Evasion (M. K. Gandhi)	14:00 – 15:30 Early Stages (R. Hoppe, J. Raemaekers) • Early-Stage Favorable HL: HD16 (A. Engert) • BREACH: Randomized Phase II Trial (M. André)	14:00 – 15:30 Immunotherapy – Clinical (P. Armand, M. Hutchings) • Checkmate 205: Cohort D (S. Ansell) • Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up (P. Bröckelmann)	14:00
Coffee Break	Coffee Break	Coffee Break	15:30
16:00 – 17:30 Advanced HL: How Can We Do Better? by Takeda/Medscape (M. Hertzberg) • Introduction (M. Hertzberg) • Can we do better in front-line? followed by iPad Audience Q&A with panel discussion (below: Q&A...) (A. Pavlovsky) • Can we do better with salvage? (Q&A...) (C. H. Moskowitz) • Assessing risk of failure throughout treatment (Q&A...) (M. Hutchings) • Conclusion (M. Hertzberg)	16:00 – 17:30 Focus on cHL: Current Insights and Future Perspectives by Bristol-Myers Squibb (P. Borchmann) • The Evolving cHL Treatment Landscape (G. Collins) • Understanding the Unmet Need in cHL (P. Borchmann) • Focus on Biomarkers: Biology as a Key Driver of Therapeutic Benefit (M. Shipp) • Panel Discussion	16:00 – 17:30 Relapsed/Refractory HL (C. H. Moskowitz, A. Sureda) • BRaVE: Phase II Trial (A. Hagenbeek) • Novel Agents in First Line Salvage (R. Advani)	16:00
Coffee Break	Coffee Break	Coffee Break	17:30
17:45 Opening Ceremony	17:45 – 19:15 Survivorship & Patients' Perspective (F. van Leeuwen, A. Plate) • What Patients Really Want: The Global Lymphoma Patient Survey (L. Warwick) • Cognitive Behavioral Therapy for Fatigue in HL (H. Knoop) • Genetic Susceptibility (L. Morton)	17:30 – 18:15 Closing Remarks	17:45
	Oral Abstract Presentations		19:15
19:45 Welcome Reception			19:45